Bawag Group AG (0B2)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 155.40 |
|---|---|
| 52-week range | 107.30 – 184.70 |
| Return, 1 month / 3 months | −12.2% / −9.3% |
| Return, 1 year / 3 years | +49.7% / +360.1% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 30 |
| Volatility (1 year) | 26.6% |
| Worst drawdown (1 year) | -16.5% |
| Average daily value traded | 0.05M EUR |
| Dividend yield | 4.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bawag Group is an Austrian bank based in Vienna that serves retail customers, small businesses and corporate clients, mainly in its home market and in Germany. It offers savings accounts, consumer and mortgage lending, credit cards, leasing and investment products, and it also runs specialised lending and factoring operations. Its customers include private individuals, self-employed people and small and medium-sized enterprises, and it operates through a branch network and digital channels.
On this site Bawag Group AG appears as a stock on the XETRA Stock Exchange (Germany), code 0B2, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bawag Group AG (0B2) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 155.40 on 23 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 173 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 49.7% and over the last three months it fell 9.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.6% | ||
| From 52-week high | -15.9% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -9.3% | ||
| 6-month return | 5.7% | ||
| 12-month return, skipping the last month | 70.5% | ||
| Stability (higher is calmer) | 82 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 26.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.5% | ||
| Liquidity | 36 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.05M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 61 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −6.8% |
|---|---|
| 1 month | −12.2% |
| 3 months | −9.3% |
| 6 months | +5.7% |
| 1 year | +49.7% |
| 3 years | +360.1% |
| 5 years | +298.5% |
Signals
| 50-day / 200-day average | 174.75 / 154.53 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.83 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Apr 2026 | EUR 6.2500 |
| 8 Apr 2025 | EUR 5.5000 |
| 10 Apr 2024 | EUR 5.0000 |
| 4 Apr 2023 | EUR 3.7000 |
| 1 Apr 2022 | EUR 3.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.